Investment Thesis
Kalaris Therapeutics exhibits severe fundamental distress with $165K revenue, $11.6M quarterly cash burn, and approximately 9 months of liquidity runway at current burn rates. While the balance sheet is unencumbered ($34.4M cash, zero debt) and losses are improving 94.5% YoY, the company faces critical refinancing or partnership requirements within 12 months absent significant clinical/commercial catalysts. Pre-revenue biotech operations are only viable with clear pathway to inflection or capital adequacy.
Strengths
- Strong balance sheet with $34.4M cash and zero long-term debt
- Excellent liquidity position with 12.19x current ratio
- Operating losses improving significantly (94.5% YoY improvement in EPS)
Risks
- Critical cash burn rate of ~$11.6M per quarter with only ~9 months of unencumbered runway
- Negligible revenue generation ($165K) with no visible near-term monetization pathway
- Extreme refinancing risk and high probability of shareholder dilution via equity raise or adverse financing terms
- Absence of long-term debt suggests potential difficulty accessing capital markets
Key Metrics to Watch
- Quarterly cash burn rate trend and runway extension
- Clinical trial progression and regulatory catalysts
- Partnership or financing announcements
- Quarterly revenue growth and customer acquisition
Financial Metrics
Revenue
165.0K
Net Income
-10.9M
EPS (Diluted)
$-0.46
Free Cash Flow
-11.8M
Total Assets
109.8M
Cash
34.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-7,171.5%
Net Margin
-6,579.4%
ROE
-15.8%
ROA
-9.9%
FCF Margin
-7,140.0%
Balance Sheet & Liquidity
Current Ratio
12.19x
Quick Ratio
12.19x
Debt/Equity
0.00x
Debt/Assets
37.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:38:33.830747 |
Data as of: 2026-03-31 |
Powered by Claude AI